Dr Daniel W Hamilton, PHD | |
9 Old Sawmill Ln, Arundel, ME 04046-8164 | |
(207) 423-7140 | |
(207) 294-4649 |
Full Name | Dr Daniel W Hamilton |
---|---|
Gender | Male |
Speciality | Psychologist |
Location | 9 Old Sawmill Ln, Arundel, Maine |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1790881928 | NPI | - | NPPES |
198160099 | Medicaid | ME |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103T00000X | Psychologist | PS1049 (Maine) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Daniel W Hamilton, PHD 33 Guinea Rd, Kennebunkport, ME 04046-5136 Ph: (207) 423-7140 | Dr Daniel W Hamilton, PHD 9 Old Sawmill Ln, Arundel, ME 04046-8164 Ph: (207) 423-7140 |
News Archive
Curing disease with neutrophils; this is the goal of the NeutroCure project. How will that work? "Neutrophils have a yin yang character," explained Andrés Hidalgo, whose team at the Centro Nacional de Investigaciones Cardiovasculares is one of six member groups participating in this project coordinated by Andriy Mokhir Friedrich from Alexander University, Germany.
Sébastien Février, reader at the University of Limoges and researcher at XLIM, and his team demonstrated that a bench-top, optical fiber-based laser source can be used to perform infrared spectromicroscopy with a precision rivaling, and in some regards even surpassing, that of experiments at large-scale synchrotron facilities.
Accelr8 Technology Corporation today announced that it completed the sale of a non-exclusive license for its proprietary OptiChem bio-coatings to an innovative, public diagnostics company. The licensee is paying $1,865,000 over four annual escalating payments and intends to use OptiChem® in its disposable diagnostic devices.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated two of the company's Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP).
This month's Ophthalmology journal includes surprising research from the Massachusetts Eye and Ear Infirmary on the relation of body weight to the risk for glaucoma. Also, from researchers at the Tokyo Medical and Dental University, comes the first specific map of how the development of myopic maculopathy, an illness that afflicts many severely nearsighted people, predicts which patients will be most susceptible to vision loss.
› Verified 1 days ago